CN113840608B - Cdk4/6抑制剂与vegfr抑制剂联合在制备***的药物中的用途 - Google Patents
Cdk4/6抑制剂与vegfr抑制剂联合在制备***的药物中的用途 Download PDFInfo
- Publication number
- CN113840608B CN113840608B CN202080038010.8A CN202080038010A CN113840608B CN 113840608 B CN113840608 B CN 113840608B CN 202080038010 A CN202080038010 A CN 202080038010A CN 113840608 B CN113840608 B CN 113840608B
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- cdk4
- administered
- days
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 title claims description 55
- 238000011282 treatment Methods 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 108091008605 VEGF receptors Proteins 0.000 title description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 title description 3
- 239000003112 inhibitor Substances 0.000 title description 3
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 229960003982 apatinib Drugs 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical group C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 208000026310 Breast neoplasm Diseases 0.000 claims description 15
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 5
- FYJROXRIVQPKRY-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid Chemical group CS(O)(=O)=O.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 FYJROXRIVQPKRY-UHFFFAOYSA-N 0.000 claims description 3
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000001613 neoplastic effect Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000269627 Amphiuma means Species 0.000 description 3
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229950001573 abemaciclib Drugs 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 3
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000011242 molecular targeted therapy Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- SGJLSPUSUBJWHO-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1C1CCNCC1 SGJLSPUSUBJWHO-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-M difluoroacetate Chemical compound [O-]C(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-M 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- -1 pamoate Chemical compound 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910052611 pyroxene Inorganic materials 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-M vanillate Chemical compound COC1=CC(C([O-])=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-M 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
CDK4/6抑制剂与VEGFR抑制剂联合在制备***疾病的药物中的用途。具体而言，CDK4/6抑制剂为式(I)所示化合物或其可药用盐，VEGFR抑制剂为阿帕替尼或其可药用盐。
Description
本申请要求申请日为2019年5月30日的中国专利申请CN201910460310.4的优先权。本申请引用上述中国专利申请的全文。
技术领域
本申请涉及一种CDK4/6抑制剂与VEGFR抑制剂联合在制备***疾病的药物中的用途。
背景技术
乳腺癌是女性最常见的恶性肿瘤之一，全世界每年约有130万新发病例。在我国，乳腺癌发病率占全身各种恶性肿瘤发病率的7％-10％，约占所有女性肿瘤的18％，目前国内患者人数已超过50万，其发病率增长迅速，在一些大城市已经位列女性肿瘤发病谱首位，并且近50％患者出现治疗后复发和转移。近年来，随着肿瘤分子生物学研究的日趋深入，分子靶向治疗在乳腺癌治疗中越来越受到广泛应用并取得了较为显著的疗效，已成为继手术、放疗和化疗三大传统模式之后一种全新的治疗模式，也是当前乳腺癌治疗领域研究的热点。
细胞周期蛋白依赖性激酶(Cyclin-dependent kinase，CDK)是一类丝氨酸/苏氨酸激酶，通过与相应的细胞周期蛋白(Cyclin)形成二聚体，进而磷酸化下游蛋白分子，从而推动细胞周期各时相的有序行进，实现细胞生长和增殖。目前，国外已有多种CDK4/6选择性抑制剂在临床试验阶段或已获批上市，其中包括辉瑞公司的Palbociclib、诺华公司的Ribociclib及礼来公司的Abemaciclib等。
WO2014183520公开了一种化学名为6-乙酰基-8-环戊基-5-甲基-2-((5-(哌啶-4-基)吡啶-2-基)氨基)吡啶并[2，3-d]嘧啶-7(8H)-酮，结构式如式(I)所示CDK4/6抑制剂，具有显著的CDK4/6的抑制活性和高度选择性，
WO2016124067A公开了上述式(I)所示化合物的羟乙基磺酸盐及其制备方法。
关于CDK4/6抑制剂与其他药物的联用已经有较多研究，WO2017193141A公开CDK4/6抑制剂与EGFR抑制剂联用可用于治疗三阴性乳腺癌；WO2016024-232A公开了CDK4/6抑制剂与BTK激酶抑制剂联用治疗癌症的方法；Lori S.Hart等人在“Preclinical TherapeuticSynergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma”中发现CDK4/6抑制剂和MEK抑制剂临床前用于成神经细胞瘤具有协同作用；CN103781480A公开CDK4/6抑制剂与FGFR激酶抑制剂的组合可用于治疗癌症；J.Bollard等“Palbociclib(PD-0332991)aselective CDK4/6 inhibitor，restricts tumour growth in preclinical models ofhepatocellular carcinoma”公开Palbociclib单药或者联用索拉菲尼可能成为治疗肝细胞癌的新策略；CN106029097A公开了abemaciclib和雷莫芦单抗联用可用于治疗非小细胞肺癌；CN108883182A公开abemaciclib和雷莫芦单抗联用可用于治疗套细胞淋巴瘤。
目前关于CDK4/6抑制剂与小分子的VEGFR抑制剂联合用于治疗癌症的用途鲜有研究。
发明内容
本申请提供一种CDK4/6抑制剂与VEGFR抑制剂联合在制备***疾病的药物中的用途。
本申请中所述的CDK4/6抑制剂可选式(I)所示化合物或其可药用盐，
本申请中，式(I)所示化合物的可药用盐选自盐酸盐、磷酸盐、磷酸氢盐、硫酸盐、硫酸氢盐、亚硫酸盐、乙酸盐、草酸盐、丙二酸盐、戊酸盐、谷氨酸盐、油酸盐、棕榈酸盐、硬脂酸盐、月桂酸盐、硼酸盐、对甲苯磺酸盐、甲磺酸盐、羟乙基磺酸盐、马来酸盐、苹果酸盐、酒石酸盐、苯甲酸盐、双羟萘酸盐、水杨酸盐、香草酸盐、扁桃酸盐、琥珀酸盐、葡萄糖酸盐、乳糖酸盐或月桂基磺酸盐，优选羟乙基磺酸盐，其结构如式(II)所示，
可选的实施方案中，所述的VEGFR抑制剂选自VEGFR-2抑制剂，优选VEGFR-2抑制剂为阿帕替尼或其可药用盐。
一些实施方案中，阿帕替尼可药用盐选自甲磺酸盐、马来酸盐、酒石酸盐、琥珀酸盐、醋酸盐、二氟醋酸盐、富马酸盐、柠檬酸盐、枸橼酸盐、苯磺酸盐、苯甲酸盐、萘磺酸盐、乳酸盐、苹果酸盐、盐酸盐、氢溴酸盐、硫酸盐、以及磷酸盐，在优选方案中，阿帕替尼的可药用盐为甲磺酸盐。
可选的实施方案中，所述VEGFR抑制剂为甲磺酸阿帕替尼。
本申请中所述的肿瘤疾病选自肉瘤、淋巴瘤、肺癌、支气管癌、***癌、胰腺癌、胃肠癌、结肠癌、直肠癌、结直肠腺瘤、甲状腺癌、肝癌、肝内胆管癌、肝细胞癌、肾上腺癌、胃癌、胃肿瘤、胶质瘤、成胶质细胞瘤、子宫内膜癌、黑素瘤、肾癌、肾盂癌、膀胱癌、子宫体癌、***、***癌、卵巢癌、多发性骨髓瘤、食管癌、白血病、急性髓细胞性白血病、慢性髓细胞性白血病、淋巴细胞性白血病、骨髓性白血病、脑肿瘤、脑癌、口腔及咽部癌、喉癌、小肠癌、非霍奇金淋巴瘤、黑素瘤、结肠绒毛腺瘤、赘生物、上皮癌、乳腺癌、基底细胞癌、鳞状细胞癌、光化性角化病、肿瘤疾病、颈部或头部肿瘤、原发性血小板增多症、髓样化生性骨髓纤维化和巨球蛋白血症，优选乳腺癌、肝细胞癌、结肠癌。
可选的实施方案中，所述乳腺癌为激素受体阳性的乳腺癌。
可选的实施方案中，所述乳腺癌为三阴性乳腺癌。
可选的实施方案中，所述乳腺癌为her2阳性乳腺癌。
可选的实施方案中，所述CDK4/6抑制剂的给药剂量选自1-500mg，优选50-200mg，更优选100-150mg，给药频次为一日一次、一日两次，优选一日一次。
可选的实施方案中，所述CDK4/6抑制剂的给药剂量50mg、75mg、100mg、125mg、150mg、175mg，优选100mg、125mg或150mg，给药频次为一日一次、一日两次，优选一日一次。
可选的实施方案中，所述VEGFR抑制剂的给药剂量为100-500mg，给药频次为一日一次、两日一次、三日一次、给药五天停药两天、给药七天停药七天。
可选的实施方案中，所述VEGFR抑制剂的剂量为200mg、225mg、250mg、275mg、300mg、325mg、350mg、375mg、500mg，优选250mg或375mg，给药频次为一日一次、给药五天停药两天、给药七天停药七天。
可选的实施方案中，所述CDK4/6抑制剂的给药剂量选自100mg、125mg或150mg，给药频次为一日一次，所述VEGFR抑制剂的剂量250mg或375mg，给药频次为一日一次、给药五天停药两天、给药七天停药七天。
可选的实施方案中，所述CDK4/6抑制剂的给药剂量为100mg，给药频次为一日一次，所述VEGFR抑制剂的剂量250mg或375mg，给药频次为一日一次、给药五天停药两天、给药七天停药七天。
可选的实施方案中，所述CDK4/6抑制剂的给药剂量为125mg，给药频次为一日一次，所述VEGFR抑制剂的剂量250mg或375mg，给药频次为一日一次、给药五天停药两天、给药七天停药七天。
可选的实施方案中，所述CDK4/6抑制剂的给药剂量为150mg，给药频次为一日一次，所述VEGFR抑制剂的剂量250mg或375mg，给药频次为一日一次、给药五天停药两天、给药七天停药七天。
本申请所述的联用的途径包括但不限于经口给药、胃肠外给药、经皮给药，所述胃肠外给药包括但不限于静脉注射、皮下注射、肌肉注射。
本申请提供一种***疾病的方法，包括给与患者治疗有效量的上述CDK4/6抑制剂和VEGFR抑制剂。
本申请提供一种药物组合物，包括上述CDK4/6抑制剂、VEGFR抑制剂以及一种或多种可药用的赋形剂、稀释剂或载体。
本申请中所述的“联合”是一种给药方式，是指在一定时间期限内给予至少一种剂量的CDK4/6抑制剂和VEGFR抑制剂，其中两种药物都显示药理学作用。所述的时间期限可以是一个给药周期内，优选4周内，3周内，2周内，1周内，或24小时以内。可以同时或不分先后顺序给予CDK4/6抑制剂和VEGFR抑制剂。这种期限包括这样的治疗，其中通过相同给药途径或不同给药途径给予CDK4/6抑制剂、VEGFR抑制剂。
附图说明
图1.xxT47D异种移植瘤模型荷瘤鼠在给予受试物后的体重变化；
图2.xxT47D异种移植瘤模型荷瘤鼠在给予受试物后的相对体重变化；
图3.各组肿瘤的生长曲线。
具体实施方式
以下结合实施例用于进一步描述本申请，但这些实施例并非限制本申请的范围。
实施例1、式(I)所示化合物羟乙基磺酸盐(药物A)单药或者联用甲磺酸阿帕替尼(药物B)在xxT47D人乳腺癌细胞(ER+，HER2-)皮下异种移植肿瘤BALB/c裸小鼠模型上的体内药效学研究
1、实验材料
药物A采用WO2016124067A公开的方法制备；
小鼠：品系：BALB/c裸小鼠；周龄及体重：6-8周龄，体重18-22克；性别：雌性；数量：42只(不包括分组剩余鼠)；供应商：上海西普尔-必凯实验动物有限公司。
细胞来源：xxT47D肿瘤细胞通过亲代T47D肿瘤细胞(来源：ATCC，HTB-133)构建的异种移植瘤体外分离建立细胞系。
2、实验方法和步骤
1)xxT47D乳腺癌模型的建立
xxT47D肿瘤细胞通过亲代T47D肿瘤细胞构建的异种移植瘤体外分离建立细胞系，同样的过程进行2次而建立完成。xxT47D肿瘤细胞体外贴壁培养，培养条件为RPMI 1640培养基中加10％胎牛血清，100U/ml青霉素和链霉素100μg/ml，在37℃ 5％CO2培养。一周两次用胰酶-EDTA进行常规消化处理传代。当细胞饱和度为80％-90％时，收取细胞，计数，接种。
2)肿瘤细胞接种
将***片(0.18mg/片)皮下接种于每只小鼠的左后背，三天后，将0.2mL(10×10e6 cells+Matrigel，体积比为1∶1)xxT47D细胞皮下接种于每只小鼠的右后背，肿瘤平均体积达到173mm3时按照实验设计(表1)开始分组给药。
表1.实验动物分组及给药方案
注：N：每组小鼠数目；给药容积：根据小鼠体重10μl/g。如果体重下降超过15％，给药方案应做出相应调整，(Vehicle A+Vehicle B)为溶剂组。
3)受试药物配置
表2.受试药物配置
4)实验指标是考察肿瘤生长是否被抑制、延缓或治愈。每周两次用游标卡尺测量肿瘤直径。肿瘤体积的计算公式为：V＝0.5a×b2，a和b分别表示肿瘤的长径和短径。
化合物的抑瘤疗效用TGI(％)或相对肿瘤增殖率T/C(％)评价。TGI(％)，反映肿瘤生长抑制率。TGI(％)的计算：TGI(％)＝【(1-(某处理组给药结束时平均瘤体积-该处理组开始给药时平均瘤体积))/(溶剂对照组治疗结束时平均瘤体积-溶剂对照组开始治疗时平均瘤体积)】×100％。
在实验结束后将检测肿瘤重量，并计算T/C weight百分比，Tweight和Cweight分别表示给药组和溶媒对照组的瘤重。
统计分析，包括每个组的每个时间点的肿瘤体积的平均值和标准误(SEM)。治疗组在试验结束时给药后第21天表现出最好的治疗效果，因此基于此数据进行统计学分析评估组间差异。两组间比较用T-test进行分析，三组或多组间比较用one-way ANOVA进行分析，如果F值有显著性差异，应用Games-Howell法进行检验。如果F值无显著性差异，应用Dunnet(2-sided)法进行分析。用SPSS 17.0进行所有数据分析。p＜0.05认为有显著性差异。3、实验结果
1)体重变化
受试物治疗对xxT47D荷瘤鼠的体重影响如图1和图2所示。
2)肿瘤体积变化
给予xxT47D荷瘤鼠受试物治疗后各组肿瘤体积变化如表3所示。
表3.各组不同时间点的瘤体积
注：a.平均值±SEM；b.给药后天数
3)肿瘤生长曲线
各组肿瘤的生长曲线如图3所示。
4)抗肿瘤药效评价指标
表4.药物A和药物B对xxT47D异种移植瘤模型的抑瘤药效评价(基于给药后第21天肿瘤体积计算得出)
注：a.平均值±SEM.b.肿瘤生长抑制由T/C和TGI(TGI(％)＝[1-(T21-T0)/(V21-V0)]×100)计算。c.p值根据肿瘤体积计算。
表5.药物A和药物B组肿瘤重量分析
注：a.平均值±SEM。b.肿瘤生长抑制由T/C重量＝TW治疗/TW对照计算。c.p值根据瘤重计算。
4、实验讨论
开始给药后21天，溶剂对照组荷瘤鼠的平均瘤体积达到1283mm3，受试物25mg/kg药物A，50mg/kg药物B组平均瘤体积分别为724mm3和704mm3，与溶剂对照组相比具有显著的抑瘤作用(p值分别为0.019和0.015)。
25mg/kg药物A联合50mg/kg药物B治疗组的平均瘤体积为354mm3，与溶剂组相比均差异显著(p＜0.001)，与各自的单药组相比，联合组均显示出更强的抗肿瘤活性，并且差异显著，药物A与药物B联用组与单药相比p值分别为0.022和0.003。肿瘤重量结果(表5)与肿瘤体积结果基本一致。
综上所述，药物A和药物B单药在试验方案剂量下在xxT47D人乳腺癌异种移植瘤模型上显示出了显著的抗肿瘤活性。与单药相比，药物A与药物B联合应用可进一步增强抗肿瘤效果。
虽然以上描述了本发明的具体实施方式，但是本领域的技术人员应当理解，这些仅是举例说明，在不背离本发明的原理和实质的前提下，可以对这些实施方式做出多种变更或修改。因此，本发明的保护范围由所附权利要求书限定。
Claims (13)
1.一种CDK4/6抑制剂与VEGFR抑制剂联合在制备***疾病的药物中的用途，所述CDK4/6抑制剂为式(I)所示化合物或其可药用盐，
所述VEGFR抑制剂为阿帕替尼或其可药用盐，所述肿瘤疾病为乳腺癌。
2.根据权利要求1所述的用途，所述式(I)所示化合物的可药用盐为羟乙基磺酸盐。
3.根据权利要求1所述的用途，所述VEGFR抑制剂为甲磺酸阿帕替尼。
4.根据权利要求1所述的用途，所述乳腺癌为激素受体阳性的乳腺癌。
5.根据权利要求1所述的用途，所述CDK4/6抑制剂的给药剂量选自1-500mg，给药频次为一日一次或一日两次。
6.根据权利要求5所述的用途，所述CDK4/6抑制剂的给药剂量选自50-200mg，给药频次为一日一次或一日两次。
7.根据权利要求5所述的用途，所述CDK4/6抑制剂的给药剂量选自100-150mg，给药频次为一日一次、一日两次。
8.根据权利要求5所述的用途，所述CDK4/6抑制剂的给药剂量为50mg、75mg、100mg、125mg、150mg、175mg，给药频次为一日一次或一日两次。
9.根据权利要求8所述的用途，所述CDK4/6抑制剂的给药剂量为100mg、125mg或150mg，给药频次为一日一次、一日两次。
10.根据权利要求5所述的用途，所述VEGFR抑制剂的给药剂量为100-500mg，给药频次为一日一次、两日一次、三日一次、给药五天停药两天、给药七天停药七天。
11.根据权利要求10所述的用途，所述VEGFR抑制剂的剂量为200mg、225mg、250mg、275mg、300mg、325mg、350mg、375mg、500mg，给药频次为一日一次、给药五天停药两天、给药七天停药七天。
12.根据权利要求11所述的用途，所述VEGFR抑制剂的剂量为250mg或375mg，给药频次为一日一次、给药五天停药两天、给药七天停药七天。
13.一种药物组合物，其包含权利要求1-12任一项所述的CDK4/6抑制剂、VEGFR抑制剂以及一种或多种可药用的赋形剂。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910460310 | 2019-05-30 | ||
| CN2019104603104 | 2019-05-30 | ||
| PCT/CN2020/093144 WO2020239051A1 (zh) | 2019-05-30 | 2020-05-29 | Cdk4/6抑制剂与vegfr抑制剂联合在制备***的药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113840608A CN113840608A (zh) | 2021-12-24 |
| CN113840608B true CN113840608B (zh) | 2023-11-14 |
Family
ID=73553499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080038010.8A Active CN113840608B (zh) | 2019-05-30 | 2020-05-29 | Cdk4/6抑制剂与vegfr抑制剂联合在制备***的药物中的用途 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN113840608B (zh) |
| TW (1) | TW202110454A (zh) |
| WO (1) | WO2020239051A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020011848A (es) | 2018-05-10 | 2021-03-29 | Regeneron Pharma | Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración. |
| CN115192720B (zh) * | 2022-05-26 | 2023-08-01 | 广东省第二人民医院（广东省卫生应急医院） | Rb1/e2f信号通路抑制剂在逆转肝癌阿帕替尼耐药中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014183520A1 (zh) * | 2013-05-17 | 2014-11-20 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN105111201A (zh) * | 2014-10-16 | 2015-12-02 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI558399B (zh) * | 2014-02-26 | 2016-11-21 | 美國禮來大藥廠 | 癌症之組合療法 |
| WO2016015604A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| WO2016024232A1 (en) * | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| EP3442572A1 (en) * | 2016-04-15 | 2019-02-20 | Eli Lilly and Company | Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma |
| WO2017193141A1 (en) * | 2016-05-06 | 2017-11-09 | Siyuan Zhang | Prognosis biomarkers and anti-tumor compositions of targeted therapeutic treatments for triple negative breast cancer |
-
2020
- 2020-05-29 WO PCT/CN2020/093144 patent/WO2020239051A1/zh active Application Filing
- 2020-05-29 TW TW109118024A patent/TW202110454A/zh unknown
- 2020-05-29 CN CN202080038010.8A patent/CN113840608B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014183520A1 (zh) * | 2013-05-17 | 2014-11-20 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN105111201A (zh) * | 2014-10-16 | 2015-12-02 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
Non-Patent Citations (1)
| Title |
|---|
| Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma;Julien Bollard等;《Gut》;第1286-1296页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202110454A (zh) | 2021-03-16 |
| WO2020239051A1 (zh) | 2020-12-03 |
| CN113840608A (zh) | 2021-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备***药物中的用途 | |
| CN110730663B (zh) | 阿帕替尼和c-Met抑制剂联合在制备***的药物中的用途 | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| CN113840608B (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备***的药物中的用途 | |
| JP2019511529A (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| Li et al. | Novel anticancer drugs approved in 2020 | |
| CN111184863B (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备***的药物中的用途 | |
| CN110840892A (zh) | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或***疾病的药物中的用途 | |
| WO2021023204A1 (zh) | Cdk4/6抑制剂与多靶点酪氨酸激酶抑制剂联合在制备***的药物中的用途 | |
| CN110585429B (zh) | 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物***疾病的用途 | |
| CN111617081B (zh) | 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途 | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| CN115721722B (zh) | 一种治疗egfr-tki耐药的非小细胞肺癌的药物组合物 | |
| WO2023051606A1 (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| JP2014034531A (ja) | Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ | |
| CN114191558A (zh) | Egfr抑制剂与抗血管新生药物在***疾病的药物中的用途 | |
| CN111821304A (zh) | 酪氨酸激酶抑制剂联合长春碱类药物在制备预防或***疾病的药物中的用途 | |
| CN113797342A (zh) | 用于预防或***疾病的治疗剂组合 | |
| WO2023111810A1 (en) | Combination therapies and uses for treating cancer | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| KR20240021237A (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| TW202317135A (zh) | 選擇性***受體共價拮抗劑與cdk4/6抑制劑聯合在製備治療乳腺癌藥物中的用途 | |
| CN117482236A (zh) | 小分子酪氨酸激酶抑制剂和stat3抑制剂在制备治疗头颈鳞状细胞癌药物中的应用 | |
| CN117545476A (zh) | 用于治疗头颈癌的egfr抑制剂 | |
| CN115006397A (zh) | 一种预防或***疾病的药物用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |